1 / 16

A risk-benefit analysis of celecoxib for the prevention of colorectal cancer

A risk-benefit analysis of celecoxib for the prevention of colorectal cancer. James Cross, MS Pharmaceutical Outcomes Research and Policy Program University of Washington ----- Biobehavioral Cancer Fellows Day April 20, 2007. The framework & decision problem.

Download Presentation

A risk-benefit analysis of celecoxib for the prevention of colorectal cancer

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. A risk-benefit analysis of celecoxib for the prevention of colorectal cancer James Cross, MS Pharmaceutical Outcomes Research and Policy Program University of Washington ----- Biobehavioral Cancer Fellows Day April 20, 2007

  2. The framework & decision problem • Nonsteroidal antiinflammatories (NSAIDs)  risk of colorectal adenoma. • NSAIDs  risk of gastrointestinal & cardiovascular adverse events. • What is the risk-benefit profile of these drugs for colorectal cancer chemoprevention?

  3. Colorectal cancer: US estimates for 20061 • Lifetime risk: 1 in 18 diagnosed with CRC. • Diagnoses: 148,610 • Deaths: 55,170 • 1 Ries L et al. SEER Cancer Statistics Review, 1975-2003, NCI. Bethesda MD. http://seer.cancer.gov/csr/1975_2003/ Based on November 2005 SEER data submission.

  4. Polyps: precursors to adenocarcinoma Standard colonoscopy Colonoscopy: current surveillance method among “high-risk” patients. Zielinski SL. JNCI 2004.

  5. NSAIDs • Non-selective inhibitors • Ibuprofen, naproxen, diclofenac • Aspirin • COX-2 selective inhibitors • Celecoxib

  6. Inflammation in colorectal cancer Ulrich C, Nat Rev Cancer 2006

  7. Evidence of benefit:NSAID vs. placebo at 3 years 1Baron JA, NEJM 2003 2Bertagnolli MM, NEJM 2006 3Arber N, NEJM 2006.

  8. Evidence of risk (CV, GI) • GI bleed risk for ASA: • OR: 1.59 (1.40-1.81)1 • OR: 1.77 (1.07-2.94)2 • CV risk for Celecoxib: 1Derry L BMJ 2000. (RCT meta-analysis, n=66,000) 2USPhysician Health Study NEJM 1989. 3 Solomon SD Circulation 2006.

  9. Current opinion of celecoxib …Due to the increased risk of CV events associated with their use, COX-2 inhibitors are not recommended routinely for sporadic adenomas. -Practice Guideline in Oncology v1.2007, Nat’l Comprehensive Cancer Network …It is reasonable to conclude that celecoxib has no role as a chemopreventive agent either in patients with nonfamilial colonic adenomas or the general population. -Psaty and Potter NEJM 2006

  10. Reasons for doing a risk benefit analysis • Proposed risks: • Cardiovascular (celecoxib) • Gastrointestinal (aspirin) • Proposed benefits: • Colonoscopies not perfectly sensitive • Slows carcinogenesis process • Decreases # of adenomas • Decision problems: • Efficacy data based on surrogate endpoint • No methodical, quantitative assessment

  11. Risk benefit analysis: methods • Objective: • compare the net health outcomes (risk & benefit) between 3 CRC prevention strategies • ASA vs celecoxib vs colonoscopy alone • Perspective: • societal perspective, 20 years • Population: • 60 years, prior finding of adenoma • Approach: • health-state transition model quantifying health outcomes over 20 year period

  12. Health-state transition model of CRC prevention Polyp free (Post-polypectomy) Advanced adenoma Death CRC GI Tox Discontinue ASA/COX CV Tox

  13. Methods: Model assumptions • GI/CV serious adverse events require drug discontinuation. • Those who discontinue drug assume health state transitions as though they were receiving only colonoscopy.

  14. Results: Net health impact # cancer case/death + # cardiovascular event/death = net health impact COMPARATOR[net health impact – REFERENCE[net health impact] • For a cohort of 100,000 (undiscounted):

  15. Limitations • Scarcity of data: • correlation between surrogate endpoints and outcomes used in decision-making. How should this be handled here, & in general? • ASA use: • How best to model cardioprotective effect of ASA use, which celecoxib users may also take? • For calculations, 1 cancer case/death = 1 GI/CV event.

  16. Acknowledgements • Dissertation committee: • Lou Garrison (UW, chair) • Scott Ramsey (UW & FHCRC) • Dave Veenstra (UW) • Funding: • Biobehavioral Cancer Prevention & Control Training Program (NCI & UW)

More Related